Eisai culls pipeline as Aricept sales plummet
This article was originally published in Scrip
Executive Summary
Eisai has discontinued one Phase III development project and dropped several others at Phase II as it reorganises R&D priorities against a background of sharply lower sales of its once blockbuster Alzheimer's disease product Aricept (donepezil).